Freeline Therapeutics Holdings ADS

  • TickerFRLN
  • ISINUS35655L1070
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited Kingdom
 PRESS RELEASE
FRLN Freeline Therap... (Health Care)

Freeline Announces Executive Leadership Changes

Freeline Announces Executive Leadership Changes Appointment of Chief Technical Operations Officer James Bircher continues evolution of leadership team to execute across near- and long-term priorities Amit Nathwani, MD, PhD to return to Chief Scientific Officer role on an interim basis to replace departing Chief Scientific Officer Romuald Corbau LONDON, June 30, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from in...

David Nierengarten
  • David Nierengarten
 PRESS RELEASE
FRLN Freeline Therap... (Health Care)

Freeline Reports First Quarter 2021 Financial Results and Recent Busin...

Freeline Reports First Quarter 2021 Financial Results and Recent Business Highlights FLT190 Phase 1/2 dose-finding study in Fabry disease on track to dose additional patients; Company to present data by year-end FLT201 Phase 1/2 dose-finding study in Gaucher disease Type 1 expected to be in the clinic by year-end FLT180a Phase 1/2 dose-confirmation study in Hemophilia B on track to initiate trial sites by year-end LONDON, May 17, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing t...

 PRESS RELEASE
FRLN Freeline Therap... (Health Care)

Freeline to Participate at the 2021 RBC Capital Markets Global Healthc...

Freeline to Participate at the 2021 RBC Capital Markets Global Healthcare Conference LONDON, May 12, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that senior management will participate in a Fireside Chat at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 4:50 pm EDT. A webcast of the event will be available on th...

 PRESS RELEASE
FRLN Freeline Therap... (Health Care)

Freeline to Present Data at the American Society of Gene and Cell Ther...

Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021 LONDON, April 27, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will give six poster presentations at the American Society of Gene and Cell Therapy Annual Meeting 2021, taking place May 11 – 14. “We are excited to be presenting six posters at the upcoming A...

 PRESS RELEASE
FRLN Freeline Therap... (Health Care)

Freeline Announces Executive Leadership Changes

Freeline Announces Executive Leadership Changes Appointment of Chief Technical Operations Officer James Bircher continues evolution of leadership team to execute across near- and long-term priorities Amit Nathwani, MD, PhD to return to Chief Scientific Officer role on an interim basis to replace departing Chief Scientific Officer Romuald Corbau LONDON, June 30, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from in...

David Nierengarten
  • David Nierengarten
 PRESS RELEASE
FRLN Freeline Therap... (Health Care)

Freeline Reports First Quarter 2021 Financial Results and Recent Busin...

Freeline Reports First Quarter 2021 Financial Results and Recent Business Highlights FLT190 Phase 1/2 dose-finding study in Fabry disease on track to dose additional patients; Company to present data by year-end FLT201 Phase 1/2 dose-finding study in Gaucher disease Type 1 expected to be in the clinic by year-end FLT180a Phase 1/2 dose-confirmation study in Hemophilia B on track to initiate trial sites by year-end LONDON, May 17, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing t...

 PRESS RELEASE
FRLN Freeline Therap... (Health Care)

Freeline to Participate at the 2021 RBC Capital Markets Global Healthc...

Freeline to Participate at the 2021 RBC Capital Markets Global Healthcare Conference LONDON, May 12, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that senior management will participate in a Fireside Chat at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 4:50 pm EDT. A webcast of the event will be available on th...

 PRESS RELEASE
FRLN Freeline Therap... (Health Care)

Freeline to Present Data at the American Society of Gene and Cell Ther...

Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021 LONDON, April 27, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will give six poster presentations at the American Society of Gene and Cell Therapy Annual Meeting 2021, taking place May 11 – 14. “We are excited to be presenting six posters at the upcoming A...

 PRESS RELEASE
FRLN Freeline Therap... (Health Care)

Freeline Announces Executive Leadership Changes

Freeline Announces Executive Leadership Changes Appointment of Chief Technical Operations Officer James Bircher continues evolution of leadership team to execute across near- and long-term priorities Amit Nathwani, MD, PhD to return to Chief Scientific Officer role on an interim basis to replace departing Chief Scientific Officer Romuald Corbau LONDON, June 30, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from in...

David Nierengarten
  • David Nierengarten
 PRESS RELEASE
FRLN Freeline Therap... (Health Care)

Freeline Reports First Quarter 2021 Financial Results and Recent Busin...

Freeline Reports First Quarter 2021 Financial Results and Recent Business Highlights FLT190 Phase 1/2 dose-finding study in Fabry disease on track to dose additional patients; Company to present data by year-end FLT201 Phase 1/2 dose-finding study in Gaucher disease Type 1 expected to be in the clinic by year-end FLT180a Phase 1/2 dose-confirmation study in Hemophilia B on track to initiate trial sites by year-end LONDON, May 17, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing t...

 PRESS RELEASE
FRLN Freeline Therap... (Health Care)

Freeline to Participate at the 2021 RBC Capital Markets Global Healthc...

Freeline to Participate at the 2021 RBC Capital Markets Global Healthcare Conference LONDON, May 12, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that senior management will participate in a Fireside Chat at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 4:50 pm EDT. A webcast of the event will be available on th...

 PRESS RELEASE
FRLN Freeline Therap... (Health Care)

Freeline to Present Data at the American Society of Gene and Cell Ther...

Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021 LONDON, April 27, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will give six poster presentations at the American Society of Gene and Cell Therapy Annual Meeting 2021, taking place May 11 – 14. “We are excited to be presenting six posters at the upcoming A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch